Stock Analysis

Viscofan, S.A. (BME:VIS) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

BME:VIS
Source: Shutterstock

Last week saw the newest half-yearly earnings release from Viscofan, S.A. (BME:VIS), an important milestone in the company's journey to build a stronger business. The result was fairly weak overall, with revenues of €303m being 2.2% less than what the analysts had been modelling. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for Viscofan

earnings-and-revenue-growth
BME:VIS Earnings and Revenue Growth August 2nd 2024

Following the latest results, Viscofan's eight analysts are now forecasting revenues of €1.25b in 2024. This would be a satisfactory 4.7% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of €1.25b and earnings per share (EPS) of €3.43 in 2024. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

We'd also point out that thatthe analysts have made no major changes to their price target of €70.84. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Viscofan at €77.00 per share, while the most bearish prices it at €62.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Viscofan's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Viscofan'shistorical trends, as the 9.5% annualised revenue growth to the end of 2024 is roughly in line with the 9.6% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 4.1% annually. So it's pretty clear that Viscofan is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of Viscofan's eight analysts has provided estimates out to 2026, which can be seen for free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Viscofan .

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.